title: Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
abstract: Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment options to individualize treatment for our patients. This article will: ∙ review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic remission throughout the day ∙ summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and ∙ discuss the various pharmacologic treatment options with a focus on recently developed molecules and novel delivery systems.
authors.affiliation: 1Washington University School of Medicine,Department of Psychiatry and Behavioral Neurosciences,St. Charles,Missouri,USA.
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Mattingly
authors.affiliation: 2Midwest Research Group,St. Charles,Missouri,USA.
authors.forename: Richard H
authors.initials: RH
authors.lastname: Anderson
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000453:epidemiology / Q000628:therapy; D000069445:Atomoxetine Hydrochloride / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology; D001714:Bipolar Disorder / Q000453:epidemiology / Q000628:therapy; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D003000:Clonidine / Q000627:therapeutic use; D015897:Comorbidity; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000453:epidemiology / Q000628:therapy; D003913:Dextroamphetamine / Q000008:administration & dosage; D016316:Guanfacine / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage
chemical_list: D018759:Adrenergic Uptake Inhibitors; D058647:Adrenergic alpha-2 Receptor Agonists; D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D008774:Methylphenidate; D016316:Guanfacine; D000069445:Atomoxetine Hydrochloride; D003000:Clonidine; D003913:Dextroamphetamine
keywords: ADHD; attention deficit/hyperactivity disorder; pharmacology; rating scales; review